MultiplexDX - Personalised Cancer Diagnosis

Interest shown

Required

120,12 %   

1 003 000 €

835 000 €

MultiplexDX, an innovative biotechnology company is developing accurate and affordable methods of personalised cancer diagnostics. The team, which consists of experienced, renowned scientists, won the Slovak Start-up Awards 2016 and has joined the New Europe 100: “Eastern Europe's emerging technology stars” compiled by Google and the Financial Times, among others.

  • Target: eliminate incorrect cancer diagnosis and save more lives thanks to the 99% accuracy of the personalised diagnostic method
  • Existing product portfolio and EUR 120K cumulative turnover since its foundation 
  • Customers include the National Institute of Health, Albert Einstein College of Medicine, Düsseldorf Universitätsklinikum, Cornell University, The Rockefeller University, Vanderbilt University
  • Team: renowned specialists in the field of biochemistry, biology and biophysics with experience from leading global research institutions including Rockefeller University and the National Cancer Institute, as well as pharmaceutical companies
Funded
Required capital
835 000 €

Total investment volume between USD 1 and 1.3 million, equivalent of EUR 835k to 1 million

Number of investors
78
Interest shown
1 003 000 €
Minimal ticket
2 000 €

Please login or register to access more information about this investment opportunity

Registration

About investment opportunity

MultiplexDX is an innovative biotechnology company founded by an international team of renowned scientists. The Company develops products that will help improve the accuracy of cancer diagnoses, reduce the number of misdiagnoses and significantly increase the number of people who survive cancer. Already actively selling to research and medical institutions, the Company is commercialising a number of products that, together with the future product pipeline, will create the targeted Multiplex 7/8/9+ technology.

The team consists of renowned biochemistry, biology and biophysics specialists with long-term experience at leading research institutions including Rockefeller University and the National Cancer Institute, as well as pharmaceutical companies. The Scientific Advisory Board of MultiplexDX has attracted globally recognised experts from multi-disciplinary fields, including a Nobel Prize laureate.

The first products of a defined product pipeline are already being sold to major research institutions and healthcare facilities. MultiplexDX is focussing its upcoming activities to primarily increase the sale of these products. Customers include renowned companies, such as the National Institute of Health, Albert Einstein College of Medicine, University of Düsseldorf, Cornell University, Rockefeller University, and Vanderbilt University.

MultiplexDX will use the investment to boost sales of existing products and to develop and validate future products from the product pipeline.

 

Web:

https://www.multiplexdx.com/

 

MultiplexDX in the media:

eTrend.sk

Expert interview with Elsevier 

Financial Times a Google 

Forbes.sk

Forbes.sk

Elsevier

HN.sk

SME

vzdravotnictve

TA3

 

Awards:

Horizon 2020 Seal of Excellence

Mladý inovatívny podnikateľ 2018

https://www1.pluska.sk/Regiony/Vychodne-Slovensko/Presovcan-vyvija-metodu-na-lepsie-diagnostikovanie-zakernej-choroby-Novy-liek-na-rakovinu

Videos

Pictures

This website uses cookies to provide the necessary site functionality and to improve your experience. By using our website, you agree to our privacy policy.